The estimated Net Worth of David P Southwell is at least $6.31 Million dollars as of 12 April 2024. Mr. Southwell owns over 99,624 units of PTC Therapeutics Inc stock worth over $4,026,780 and over the last 14 years he sold PTCT stock worth over $1,942,178. In addition, he makes $342,605 as Independent Director at PTC Therapeutics Inc.
David has made over 10 trades of the PTC Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 99,624 units of PTCT stock worth $432,368 on 12 April 2024.
The largest trade he's ever made was exercising 99,624 units of PTC Therapeutics Inc stock on 12 April 2024 worth over $432,368. On average, David trades about 6,941 units every 92 days since 2010. As of 12 April 2024 he still owns at least 124,784 units of PTC Therapeutics Inc stock.
You can see the complete history of Mr. Southwell stock trades at the bottom of the page.
David P. Southwell serves as Independent Director of the Company. He is currently the Chief Executive Officer, and a member of the board of directors, of TScan Therapeutics, Inc., a privately-held biotechnology company at which he has held this position since October 2018. Previously Mr. Southwell served as President and Chief Executive Officer of Inotek Pharmaceuticals, Inc., a biotechnology company, from 2014 until its merger with Rocket Pharmaceuticals Inc. in 2018. From March 2010 to September 2012, Mr. Southwell served as the Executive Vice President and Chief Financial Officer, and from 2008 to 2010 served as a member of the board of directors, of Human Genome ciences, Inc., a biopharmaceutical company. Prior to joining Human Genome Sciences, he served as Executive Vice President and Chief Financial Officer of Sepracor, Inc., a research-based pharmaceutical company, from June 1994 to March 2008, and as Sepracor's Senior Vice President and Chief Financial Officer, from 1994 to 1995. From August 1988 until 1994, Mr. Southwell was associated with Lehman Brothers Inc., a securities firm, in various positions within the investment banking division. In addition to TScan, Mr. Southwell currently serves on the boards of Spero Therapeutics, Inc. and Rocket Pharmaceuticals, both Nasdaq-listed biotechnology companies. During 2016, Mr. Southwell served as a director of inVentiv Health, Inc., a contract research organization prior to its recapitalization in late 2016. From 2007 to 2016, Mr. Southwell served on the board of directors of THL Credit, Inc., a Nasdaq-listed business development company under the Investment Company Act of 1940. Mr. Southwell received a B.A. from Rice University and an M.B.A. from the Tuck School of Business at Dartmouth College, where he currently serves as a member of the Board of Advisors.
As the Independent Director of PTC Therapeutics Inc, the total compensation of David Southwell at PTC Therapeutics Inc is $342,605. There are 11 executives at PTC Therapeutics Inc getting paid more, with Stuart Peltz having the highest compensation of $7,759,440.
David Southwell is 59, he's been the Independent Director of PTC Therapeutics Inc since 2005. There are 10 older and 6 younger executives at PTC Therapeutics Inc. The oldest executive at PTC Therapeutics Inc is Dr. Allan Steven Jacobson, 75, who is the Independent Co-Founder, Chairman of Scientific Advisory Board & Director.
David's mailing address filed with the SEC is C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY, NJ, 08512.
Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel, and Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
PTC Therapeutics Inc executives and other stock owners filed with the SEC include: